The global pandemic radically accelerated changes in our industry, including the rapid uptake of decentralized clinical trials. Now that the dust is settling, it is important to better understand the many options and technologies available in our toolbox and to apply these in a thoughtful way in order to ensure trial success.
In this panel discussion at the Clinical Trial Partnerships in Oncology conference, our own Patrick Melvin, Noolie Gregory and Dave Thompson address key considerations for applying decentralized solutions for oncology including the long term follow-up aspects to meet the needs of multiple stakeholders, including sites, patients, regulators and payers.
